PRDX1 and cancer: Silencing Prx1 resulted in inactivation of the NF-κB pathway and suppression of the EMT process, suggesting that Prx1 is a potential therapeutic target for cancer cell EMT.171 As mentioned above, EMT confers cancer cells with CSC characteristics so that they can escape from chemotherapeutic stress.